PPARG and Stroke: For proof of concept, indeed, knocking down EZH2 in hMSCs or treatment with PPARγ agonist after hMSCs implantation significantly improved behavioural measures of neurological deficit after stroke in the animal model, opening an avenue for using hMSC transplantation to treat neurodegenerative diseases.